The aim of this cross-sectional study which took place in a hypertension clinic at a district general hospital in Denmark was to make a pragmatic definition of white coat hypertension. A total of 420 patients were referred consecutively from general practice with newly diagnosed untreated essential hypertension and 146 normal subjects were drawn at random from the Danish national register. The following measurements were taken: office blood pressure; 24-h ambulatory blood pressure (BP) monitoring; echocardiography with determination of left ventricular mass index and relative wall thickness; and early morning urine albumin/creatinine ratios.
Introduction
Blood pressure (BP) measured under standardised conditions at the office and BP during daily life as measured by ambulatory monitoring often give different results. The correlation between values from these two measurement modalities is relatively low with reported coefficients of correlation around 0.5-0.7. [1] [2] [3] It is unsolved which measure is 'true', ie, which best reflects the 'usual' BP and prognosis. 4 The lack of identity between the two methods of measurement yields a group of patients with the combination of hypertensive office BP and normal ambulatory BP (ABP), which is generally referred to as 'white coat hypertension'. 5, 6 The literature has shown numerous definitions of this condition and, consequently, great variation in the characterisation of the group has evolved. 7 The primary explanation for these diversities is the lack of widely accepted ABP normalcy limits. The cut-off values between normal and hypertensive office BP has been determined on the basis of major epidemiological longitudinal studies regarding BP level and frequency of Correspondence: Dr A Høegholm, Medicinsk Afdeling, Centralsygehuset, DK-4700 N stved, Denmark Received 26 January 1998; revised 7 April 1998; accepted 16 April 1998 atory daytime BP of 135.6/90.4 mm Hg was found to correspond to an office BP of 140/90 mm Hg in normal controls; used as a cut-off level in patients with newly diagnosed hypertension it separated 19% as white coat hypertensives. The end-organ involvement of these white coat hypertensives differed significantly from those with established hypertension but not from the normal controls. Lower cut-off levels were less efficient in this respect, as was the case when the systolic BP was not taken into account.
In conclusion a pragmatic definition of white coat hypertension should-apart from well-established hypertensive office measurements-include a cut-off level close to 135/90 mm Hg ambulatory daytime BP.
morbid and mortal events 4, 8 and intervention studies; 9 a value of 140/90 mm Hg is widely accepted for adults. 10, 11 In contrast, no similar large scale studies on morbidity/mortality and ABP exist, and hence cut-off values for ABP have not gained consensus. 12 This dilemma had led to a disputable practise in which cross-sectional studies on 'normal populations' of limited size have been the substrates for different types of computations. Most often a percentile or standardised deviation from the mean of the distribution is computed, in other cases a BP of 140/90 mm Hg at the office has been used to calculate a corresponding ABP value. Some studies make conversions for different gender and age groups separately, which makes the results less easy to handle in clinical practice. 2 Evidently, the varying cut-off levels give very large differences in the frequency of white coat hypertension, ie, 7-52%. [13] [14] [15] [16] In the absence of large scale longitudinal studies and generally accepted cut-off values we have made the present analysis on BP and surrogate end-points with the purpose of examining the effect of different cut-off levels for the definition of normalcy and hence white coat hypertension. Our cohort of patients offers a potential for describing a white coat group with a normal level of target organ involvement, in that it includes a genuine normal control group and has data on both albuminuria and echocardiography.
Subjects and methods
In order to estimate the frequency of white coat hypertension we have performed 24-h ABP monitoring in 420 consecutive patients with newly diagnosed mild-to-moderate hypertension. The inclusion criterion was that their general practioner had planned to start anti-hypertensive treatment, but had not yet instituted it. In order to avoid confounding, patients with other known reasons for albuminuria, eg, known diabetes or renal disease, were excluded from the statistical analyses regarding albuminuria data. No patients with major cardiovascular diseases were included.
As part of a multicentre study to establish the distribution of ABP in the population, 17 we performed 24-h BP monitoring in subjects drawn at random from the Danish national register. There was an intended similar number of subjects in different gender and age strata from 20-79 years. Subjects with known renal or cardiovascular disease, diabetes, hypertension or other condition necessitating therapy with drugs with anti-hypertensive effects had been excluded, leaving 146 monitorings.
The study was in accordance with The Second Declaration of Helsinki, and was approved by the local ethics committee. All participating subjects gave their informed consent.
Blood pressure measurements
All the referred patients were considered by their general practioner to have hypertension, and were scheduled to start anti-hypertensive treatment in the near future. No patient had for the 5 weeks prior to the study received any anti-hypertensive drug; no patient was taken off medication in order to enter the study, but, a third had previously been on such medication (most often because of previous hypertension, but also large numbers because of palpitations, oedema and tremor) which had been taken for median 3 years. The BP of the patients who had never been on anti-hypertensive medication had been followed by the general practitioners for median 4 months. The practitioners had determined the BP at least three times (median 4) with at least weekly intervals. Nearly everybody used a standard size cuff (12 × 35 cm) and in the sitting position; approximately a third used aneroid sphygmomanometers, the remainder mercury columns. The average of the diastolic BP measured in this way was above 90 mm Hg in all subjects.
The office BP of the normotensive subjects was determined as a mean of five measurements with a Hawksley 'random zero' sphygmomanometer (Hawksley and Sons Ltd, Lancing, UK), 18 performed in the sitting position after 15-min of rest in the hypertension clinic.
The subjects wore TM 2420 ABP recorders (A&D, Tokyo, Japan) 19, 20 for at least 24 successive hours on working days, during which period they performed their habitual daily activities; the recorders took readings every 15 min 07.00 am to 10.59 pm and every 30 min 11.00 pm to 06.59 am. In 17 subjects (3%) less than 40% of the stipulated measurements were obtained, but all ambulatory readings were considered acceptable, defined as at least 18 daytime readings from outside the office.
The monitorings were edited for supposedly artifactual measurements, ie, single measurements associated with either an unexplained pulse rate above 120/min, or an unexplained systolic or diastolic pressure deviation exceeding 30% compared with the readings immediately before and after. The subjects did not wear activity monitors or the like, but according to their diaries almost everybody was awake throughout the period between 08.00 am to 09.59 pm, which was subsequently defined as the daytime period, and the daytime ABP was the average of the readings obtained in this period.
Echocardiography
One hundred and thirty-two (132) of the 146 normal subjects (90.4%) and 333 of the 420 hypertensive patients (79.3%) were examined with echocardiography. The same experienced physician examined all subjects with an Aloka 720 SSD mechanical sector scanner (Aloka, Tokyo, Japan). All the examinations were videotaped. In the parasternal short-axis view two to four M-mode photographs were taken at the optimum perpendicular plane just below the tips of the mitral leaflets. These photographs were evaluated independently by two observers, who were blind regarding the age, gender, size, and BP of the subjects. The two observers could individually inspect the videotapes, if it was felt necessary. All evaluations were performed in the same batch; hence, the readings were different from the data previously reported. 21 The reason for the blinding procedure was to assure an estimate free from bias, but of course at the cost of lower accuracy which, however, is of less importance due to the relatively high number of subjects. No patient was excluded from analysis because of difficulties in obtaining images, although 55 (11.4%) were considered of minor technical quality. Interventricular septal thickness (IVST), posterior wall thickness (PWT), and enddiastolic left ventriculum internal diameter (LVID) were determined according to the Penn-convention. 22 Left ventricular mass was computed as 1.04
] − 13.6 g 22 and was indexed for body surface area (BSA) (left ventricular mass index (LVMI)); relative wall thickness (RWT) was computed as 2 × PWT/LVID. 23 The between-observer coefficients of variation were 10.8% and 9.5% for LVMI and RWT, respectively. The mean of the measurements of the two observers was used for data analysis.
Urinalysis
All the subjects were asked to bring with them an early morning urine sample, defined as the first voided specimen on arising; 127 of the 146 normal subjects (87.0%) and 302 of the 420 hypertensive patients (71.9%) complied in this regard. The urine samples were stored at −20°C, until analyses were carried out using the same batches of reagents. Albumin concentrations were determined by an immu-435 nonephelometric technique. 24 Creatinine concentrations were measured by the routine Jaffé method (SMA-II, Technicon, Tarrytown, NY, USA). The results from this analysis have previously been published in another context. 25 Albuminuria was estimated as the ratio between albumin and creatinine. The day-to-day coefficient of variation for this measurement is 22.8% in normal subjects. 25 
Statistical analyses
Data are expressed as mean ± s.d. unless otherwise stated; since the microalbuminuria data are skewed, they were transformed logarithmically before being statistically tested. ⌾ 2 test was used for group comparisons regarding categorised data. Group concentrations regarding continuous variables were performed with unpaired t-test or one-way analysis of variance followed by Student-Newman-Keul's procedure if more than two groups were analysed. In order to define cut-off levels, simple regression analysis between office and ambulatory daytime BPs were performed in the normal controls, and the ambulatory level corresponding to 140/90 mm Hg at the office was determined (later referred to as the regression method). Another cut-off level was produced by determining which percentiles in normal controls correspond to 140/90 mm Hg, the same percentiles were then applied to the ambulatory data (later referred to as equal percentile method). P Ͻ 0.05 was considered significant. All computations were carried out with SPSS/PC+ V2.0 software (SPSS, Chicago, IL, USA).
Results
The subjects characteristics are shown in Table 1 . Most of the BP data differ significantly, as could be expected, but age and body mass index (BMI) differ as well. The difference regarding age is explained by the fact that the normal controls were recruited with an intended even age stratification.
The daytime ABP cut-off level between normotension and hypertension has a pronounced effect on the amount of end-organ involvement in the resulting groups. Figure 1 shows the relation between the cut-off level and the percentage of endorgan involvement in the group of newly diagnosed hypertensives. In this analysis the 95th percentiles of ecco-and albuminuria-data in the normal control group were defined as the levels above which endorgan involvement was present. For the ratio between albumin and creatinine (on a molar basis after logarithmic transformation) the 95th percentile was 0.26. For RWT and LVMI it was 0.45 and 148.1 g/m 2 , respectively. These levels are higher than reported by others, 22, 23 probably due to the efficient blinding procedure causing a larger scatter about the mean. There was a significant gender difference in echocardiographic data but not in albuminuria.
For men the mean LVMI was 110.7 ± 26.7 g/m 2 and mean RWT 0.36 ± 0.06; the corresponding values for women were 85.8 ± 26.0 g/m 2 and 0.34 ± 0.06. However, substituting gender-based 95th percentiles (which are less reliably defined due to a lower number of subjects) for the above mentioned had no significant influence on the results and was therefore not used.
The cut-off level has an impact on the resulting prevalence of white coat hypertension, too. for diastolic ambulatory daytime BP, the percentage of white coat hypertension is 30.7%. If the cut-off level is 135/85 mm Hg ambulatory daytime BP, as proposed by some groups, 12 the percentage of white coat hypertension is calculated to 9.3%. It is widely accepted that 140/90 mm Hg measured at the office can be considered normotensive. 10, 11 This office measurement was transformed into corresponding ambulatory daytime measurements in two ways. Firstly, the simple regression method 15 gives a cutoff level of 135.6/90.4 mm Hg daytime ABP. Secondly, in the normal controls an office BP of 140/90 mm Hg correspond to percentile 71.9 for systolic and 80.8 for diastolic pressure; when the same pecentiles are applied to the ambulatory data a cutoff level of 139.6/89.4 mm Hg is found. These two cut-off levels yield percentages of white coat hypertensives amounting to 19.0% and 18.6%, respectively, if applied to the hypertensive group.
The influence of the four cut-off levels on endorgan involvement in the resulting groups of white coat hypertensives and established hypertensives is shown in Table 2 .
The influence of the office BP on the frequency of white coat hypertension can be calculated. Table 3 shows the frequency of white coat hypertension in the group of newly diagnosed hypertensives, according to different levels of office BP; the cut-off level in this table is 135.6/90.4 mm Hg (with a white coat percentage of 19.0%), as derived by the regression method.
If the 45 of the 146 normal controls (30.8%) who did not have an office BP below 140/90 mm Hg were excluded from the analyses of target organ damage given in Table 2 , the results deviate modestly. The mean values in the normotensive group were 92.0 g/m 2 for LVMI, 0.341 for RWT and −0.220 for albuminuria; all four groups of patients with established hypertension (see Table 2 ) were still significantly different from the normotensive controls, but only by using definition #2 (equal percentile method) and #3 (regression method) the resulting groups of white coat hypertensives ended up with target organ involvement significantly lower than the corresponding established hypertensives but not different from the normotensive controls.
The percentage of the normal controls who are not normotensive differ according the selected cut-off level. Definition #1 (cut-off 90 mm Hg diastolic ambulatory daytime BP) makes 18.5% of the normals non-normotensive, whereas the corresponding figures for the other definitions are: definition #2 
Discussion
We have aimed at describing a 'real' white coat hypertensive group as individuals with the highest ambulatory systolic and diastolic values but without a greater extent of target organ damage than a normal control group. Our study was conducted on con- secutive patients referred per protocol from general practice with newly diagnosed hypertension and with the practitioner intending to start pharmacologic anti-hypertensive treatment. Furthermore, for comparison, we included a control group of nontreated healthy individuals drawn at random from the national register.
The main finding from our study is that in the hypertensive population daytime ABP below levels in the range of 135.6-139.6/89.4 -90.4 mm Hg is associated with the lowest prevalence of end-organ damage, and that white coat hypertension defined on this basis is not significantly different from the normal control group in this regard ( Table 2) .
The association between BP cut-off level and the presence of different forms of end-organ is illustrated in Figure 1 . It should be noted that only a few patients have very low BP (27 were below 120 mm Hg systolic and 15 below 80 mm Hg diastolic), thus explaining the fluctuation of the curves at the lower end of BP levels; furthermore, regarding microalbuminuria the J-shaped curve could be partly explained by the presence of three patients (all younger women) with microalbuminuria in spite of low ABPs. It is interesting to note that the presence of end-organ damage seems to be largely unrelated to the diastolic BPs, whereas the impact of systolic ABP is much stronger. The threshold where the prevalence of end-organ damage increases seems to be in the BP range of 130-145 mm Hg systolic with no obvious threshold for the diastolic pressures. It could be argued that this lack of a clearcut threshold is explained by the significant gender difference in RWT and LVMI, but also when analysing the data for men and women separately no definite threshold level can be deduced. Figure 2 shows that apart from influencing the extent of end-organ damage the frequency of white coat hypertension in the referred (hypertensive) individuals is also determined by the applied systolic and diastolic cut-off values. We have focused on four different cut-off levels derived from the literature, the tradition and two different ways of transforming the generally accepted WHO-limits from office into ABP. The definitions and the calculated resulting frequencies of white coat hypertension among the patients with newly diagnosed hypertension were as follows: (1) giving a prevalence of 9.3% white coat hypertension.
If the systolic BP was not taken into account at all (definition #1), the albumin excretion in the resulting white coat group was higher than in the normal controls, as we have published previously. 25 When the cut-off criterion was sharpened by including the systolic BP as in definition #2 (around 140/90 mm Hg) the white coat group had an albumin excretion and an LVMI similar to the normal controls but an RWT not significantly different from the established hypertensives. When the cut-off criterion was made more rigorous (around 135/90 mm Hg as in definition #3) the differentiation seemed optimum. By sharpening the cut-off criterion even further to 135/85 mm Hg (definition #4) the differentiating power was lost regarding echocardiographic data. Thus, our data indicate that a daytime ABP of around 135/90 mm Hg is the proper discriminating level for white coat hypertension. This limit is somewhat higher than reported by others; the explanation for this can-apart from the different methodologies-rely on the different populations studied, eg, unlike in mediterranean countries 2 the 'siesta effect' is not discernible in the 24-h BP profiles in the northern European countries. 17 If one accepts the cut-off criterion as suggested from our data, the prevalence of white coat hypertension is approximately 19% among patients with newly diagnosed mild-to-moderate hypertension, a somewhat lower figure than previously reported, 6 but similar to the figures reported by others. 29 It is obvious, though that the frequency of white coat hypertension is declining with more severe office BP elevations at admission, as is illustrated in Table 3 , where 135.6/90.4 mm Hg is the cut-off criterion (definition #3 from Table 2 ). It is seen that if the office BP is above 160/100 mm Hg the probability of white coat hypertension is materially reduced. Verdecchia et al 29 have reported a similar relationship.
The opinions on the white coat problem have shown remarkable fluctuation during the last decade. From being a condition regarded as potentially benign and a source of overtreatment with antihypertensive medications, the tide has now shifted towards sceptiscism and a fear that the condition is a prehypertensive state 30 that actually has cardiovascular dysfunction 13 and signs of target organ damage 25 leaving anti-hypertensive treatment considerable after all. However we find the evidence supporting these viewpoints still rather weak. Although the study by Bidlingmeyer et al 30 is longitudinal, is is essentially a re-examination of probably very selected patients with a very low followup rate. The study by Glen et al 13 is flawed in several aspects. The authors applied a very high cut-off level of 95 mm Hg diastolic ABP yielding a very high white coat percentage in spite of the tertiary setting; the normotensive controls were recruited by virtue of their referral to the hypertension clinic (!); ecco-doppler data insinuated incipient diastolic dysfunction in the white coat group, but are probably the result of erroneous calculations. 31 Our own previous study on albuminuria 25 supported the view that white coat hypertensives were at intermediate risk; however, these data were produced in the era of minor emphasis on systolic BP, in that we had defined white coat hypertension only on the basis of daytime diastolic ABP being below 90 mm Hg (as is the case in definition #1 in Table 2 ). In the present study it is shown that when daytime systolic ABP below 135-140 mm Hg is included in the definition there is no significant difference between white coat hypertensives and the normal group, neither regarding microalbuminuria nor echocardiographic data.
At present there are a number of cross-sectional studies, 14, 32, 33 but only two longitudinal studies 34, 35 implying the benign nature of white coat hypertension; of course, further prognostic studies are awaited with great interest. Meanwhile the present cross-sectional study supports the view that white coat hypertensives, when properly defined, are at the same risk as normal controls.
The main limitation of our study is its crosssectional nature. Another limitation is that a large fraction of the normal controls had an office BP exceeding 140/90 mm Hg. This does not imply that they are hypertensive, mainly because such a diagnosis has to be based on several measurements with adequate time intervals. However, this way of measuring BP is the same as the majority of the epidemiological studies have used, and therefore it can be assumed that a BP measured in this way which is lower than 140/90 mm Hg is associated with very low risk. If the 30.8% of the normal subjects with office BPs above 140/90 mm Hg are excluded from the analysis of end-organ damage shown in Table 2 we still find that criterion #3 (the regression method) defines white coat hypertensives with significantly less end-organ involvement than established hypertensives but without significant differences from the normotensive controls. A final limitation of our study is that the key computations rely on one definition of a normal amount of end-organ damage, thus disregarding the independent gender-and agerelated differences in echocardiographic variables. The main reason for this choice of method is that the sample size of our normal subjects is too small to allow such subdivisions, but control computations where the gender-related differences were taken into account showed that this had no significant effect on the results.
Conclusively, our findings suggest that in round numbers a cut-off level of 135/90 mm Hg daytime ABP is considered for the definition of normalcy, in that white coat hypertensives defined in this way have a similar level of target organ involvement as have normal controls. Such a cut-off level yields approximately 19% white coat hypertensives among newly diagnosed patients with mild-to-moderate hypertension.
